MARKET

CMRX

CMRX

Chimerix
NASDAQ
2.150
-0.070
-3.15%
After Hours: 2.170 +0.02 +0.93% 17:42 12/06 EST
OPEN
2.220
PREV CLOSE
2.220
HIGH
2.260
LOW
2.150
VOLUME
1.20M
TURNOVER
0
52 WEEK HIGH
7.42
52 WEEK LOW
1.270
MARKET CAP
189.30M
P/E (TTM)
1.235
1D
5D
1M
3M
1Y
5Y
Health And Human Services Issues Statement On Mpox; Says Does Not Expect That It Needs To Renew The Emergency Declaration When It Ends On January 31, 2023
Benzinga · 4d ago
Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?
Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks · 11/29 17:00
World Health Organization Announces Term 'mpox' As New Name For Monkeypox, With Old Name Phased Out Over Coming Year
Benzinga · 11/28 13:45
Chimerix Earnings Perspective: Return On Invested Capital
Benzinga · 11/21 14:50
Chimerix Rejects Shareholder Rubric Capital Management's Call for Liquidation
Chimerix Rejects Shareholder Rubric Capital Management's Call for Liquidation
MT Newswires · 11/11 06:27
Chimerix rejects calls for liquidation from Rubric Capital Management
Seekingalpha · 11/10 22:59
BRIEF-Chimerix Responds To Rubric Capital Management
Reuters · 11/10 22:18
Chimeric climbs 14% as Rubric Capital reports 8.5% stake, liquidation in sight
Seekingalpha · 11/10 20:40
More
About CMRX
Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. Imipridones targets specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC201 is in a phase II trial to treat neuroendocrine tumors (Pheochromocytoma/paraganglioma). Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP.

Webull offers kinds of Chimerix Inc stock information, including NASDAQ:CMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMRX stock methods without spending real money on the virtual paper trading platform.